Switch theme
Sign up to access all valuation multiples
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).
1928
9.4K+
LTM Revenue $6.8B
LTM EBITDA $1.8B
$29.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
UCB has a last 12-month revenue of $6.8B and a last 12-month EBITDA of $1.8B.
In the most recent fiscal year, UCB achieved revenue of $6.6B and an EBITDA of $2.1B.
UCB expects next 12-month revenue of XXX and NTM EBITDA of XXX
See UCB valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $5.6B | $6.6B | XXX | XXX | XXX |
| Gross Profit | $4.1B | $3.8B | XXX | XXX | XXX |
| Gross Margin | 73% | 58% | XXX | XXX | XXX |
| EBITDA | $1.4B | $2.1B | XXX | XXX | XXX |
| EBITDA Margin | 24% | 32% | XXX | XXX | XXX |
| Net Profit | $449M | $368M | XXX | XXX | XXX |
| Net Margin | 8% | 6% | XXX | XXX | XXX |
| Net Debt | $2.0B | $2.2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, UCB's stock price is EUR 139 (or $149).
UCB has current market cap of EUR 26.4B (or $28.4B), and EV of EUR 27.7B (or $29.8B).
See UCB trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $29.8B | $28.4B | XXX | XXX | XXX | XXX | $6.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, UCB has market cap of $28.4B and EV of $29.8B.
UCB's trades at 4.4x LTM EV/Revenue multiple, and 16.8x LTM EBITDA.
Analysts estimate UCB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for UCB and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $29.8B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 14.1x | XXX | XXX | XXX |
| P/E | 24.8x | XXX | XXX | XXX |
| P/E/Growth | 1.1x | XXX | XXX | XXX |
| EV/FCF | 30.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpUCB's NTM/LTM revenue growth is 12%
UCB's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, UCB's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate UCB's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for UCB and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 32% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 44% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 57% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
UCB acquired XXX companies to date.
Last acquisition by UCB was XXXXXXXX, XXXXX XXXXX XXXXXX . UCB acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was UCB founded? | UCB was founded in 1928. |
| Where is UCB headquartered? | UCB is headquartered in Belgium. |
| How many employees does UCB have? | As of today, UCB has 9.4K+ employees. |
| Who is the CEO of UCB? | UCB's CEO is Mr. Jean-Christophe Tellier. |
| Is UCB publicy listed? | Yes, UCB is a public company listed on BRU. |
| What is the stock symbol of UCB? | UCB trades under UCB ticker. |
| When did UCB go public? | UCB went public in 1988. |
| Who are competitors of UCB? | Similar companies to UCB include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of UCB? | UCB's current market cap is $28.4B |
| What is the current revenue of UCB? | UCB's last 12-month revenue is $6.8B. |
| What is the current EBITDA of UCB? | UCB's last 12-month EBITDA is $1.8B. |
| What is the current EV/Revenue multiple of UCB? | Current revenue multiple of UCB is 4.4x. |
| What is the current EV/EBITDA multiple of UCB? | Current EBITDA multiple of UCB is 16.8x. |
| What is the current revenue growth of UCB? | UCB revenue growth between 2023 and 2024 was 17%. |
| Is UCB profitable? | Yes, UCB is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
